RT Journal Article
SR Electronic
T1 A prospective, split-Face, comparative study of combined Q-switch Nd:YAG laser and microdermabrasion versus Q-switch Nd:YAG laser alone in treatment of melasma
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.19.21257291
DO 10.1101/2021.05.19.21257291
A1 Hatami, Parvaneh
A1 Asl, Hamed Nicknam
A1 Aryanian, Zeinab
YR 2021
UL http://medrxiv.org/content/early/2021/05/22/2021.05.19.21257291.abstract
AB Background Melasma is a common disorder of hyperpigmentation with a great effect on quality of life. In an uncontrolled study, a novel combination treatment approach, using a low-fluence Q-switched (QS) Neodymium-doped Yttrium Aluminium Garnet (Nd:YAG) Laser in conjunction with microdermabrasion was shown to be effective in clearance of melasma(1).Objective The purpose of the current prospective, controlled study was to determine if microdermabrasion, when combined with Nd:YAG laser, produced significant improvement of melasma compared to Nd:YAG laser alone.Methods Twenty patients with bilaterally distributed facial melasma were subjected to QS-Nd:YAG laser therapy with microdermabrasion on one side and laser therapy alone on the other side of their faces every four weeks for three sessions. Photographs were obtained before treatment, one month and three months postoperatively.Results Although both sides improved from baseline to the 24th week, there was no statistically significant difference between both sides in regards to MASI (Melasma Area and Severity Index) as well as PGA (Patient Global melasma improvement Assessment) scores.Conclusion Combination therapy with Q-switched Nd:YAG laser and microdermabrasion seems to be as effective as Q-switched Nd:YAG laser alone and doesn’t have any advantage or disadvantage in comparison with conventional laser therapy.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialIRCT20191228045917N2Funding StatementThe authors thank Iran National Elites Foundation for providing financial support.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below: Vice Chancellor for Research & Technology, Rafsanjan University of Medical Sciences, Central Office, Imam Ali Blvd., Rafsanjan, Iran Approval ID: IR.RUMS.REC.1394.279 Approval statement: The project was found to be in accordance to the ethical principles and the national norms and standards for conducting Medical Research in IranAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author